| Open Document File Size: 1,78 MBShare Result on Facebook
City Halifax / Berlin / Dalheim / / Company Montgomery SA. / Lundbeck Canada Inc. / MEDLINE / Philips / Aquila / Barr LC / / Country Canada / United Kingdom / / Event Product Recall / Product Issues / / Facility AJL Building / Arch Gen Psychiatry / Dalhousie University / / IndustryTerm treatment of depression / treatment of panic disorder / / MedicalCondition discontinuation syndrome / headaches / paresthesia and visual disturbances / headache / Discussion SSRI discontinuation syndrome / Fluoxetine withdrawal symptoms / panic disorder / original psychiatric illness / Dilsaver S. Antidepressant withdrawal syndrome / nausea / tremor / serotonergic withdrawal syndrome / fatigue / diarrhea / restlessness / Neurologic symptoms / SSRI discontinuation syndrome / ataxia / Selective serotonin reuptake inhibitor discontinuation syndrome / light-headedness / insomnia / la fatigue / obsessive compulsive disorder / parkinsonism / anxiety disorders / cognitive impairment / vertigo / disorientation / mental disorder / Georgian F. Orthostatic hypotension / movement disorders / Medication withdrawal symptoms / dizziness / Szabadi E. Fluoxetine withdrawal syndrome / withdrawal symptoms / depression / Serotonin reuptake inhibitor discontinuation syndrome / paresthesia / syndrome / paroxetine withdrawal syndrome / akathisia / / MedicalTreatment Pharmacotherapy / / Organization Department of Psychiatry / Health Sciences Centre / Kutcher Department of Psychiatry / Dalhousie University / / Person Serdar Dursun / Kathy Black / Severe / Haddad P. Newer / Elizabeth / Cathy Shea / Berk M. Paroxetine / Stanley Kutcher / / Position Queen / physician / Pinofsky HB / / Product antipsychotic drugs / Neuroleptic / drome / symptoms / reactions / Nikon D40 Digital Camera / Sertraline / fluoxetine / Celexa / syndrome / phenomena / TCA / Dilsaver S. Antidepressant / DV / Dilsaver S. Heterocyclic / Szabadi E. Fluoxetine / Einbinder E. Fluoxetine / / Technology AV / /
SocialTag |
Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria